» Articles » PMID: 25909629

Characterization of Burkholderia Pseudomallei Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays

Overview
Journal PLoS One
Date 2015 Apr 25
PMID 25909629
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Burkholderia pseudomallei, the etiologic agent of melioidosis, is a gram-negative facultative intracellular bacterium. This bacterium is endemic in Southeast Asia and Northern Australia and can infect humans and animals by several routes. It has also been estimated to present a considerable risk as a potential biothreat agent. There are currently no effective vaccines for B. pseudomallei, and antibiotic treatment can be hampered by nonspecific symptomology, the high incidence of naturally occurring antibiotic resistant strains, and disease chronicity. Accordingly, there is a concerted effort to better characterize B. pseudomallei and its associated disease. Before novel vaccines and therapeutics can be tested in vivo, a well characterized animal model is essential. Previous work has indicated that mice may be a useful animal model. In order to develop standardized animal models of melioidosis, different strains of bacteria must be isolated, propagated, and characterized. Using a murine intraperitoneal (IP) infection model, we tested the virulence of 11 B. pseudomallei strains. The IP route offers a reproducible way to rank virulence that can be readily reproduced by other laboratories. This infection route is also useful in distinguishing significant differences in strain virulence that may be masked by the exquisite susceptibility associated with other routes of infection (e.g., inhalational). Additionally, there were several pathologic lesions observed in mice following IP infection. These included varisized abscesses in the spleen, liver, and haired skin. This model indicated that commonly used laboratory strains of B. pseudomallei (i.e., K96243 and 1026b) were significantly less virulent as compared to more recently acquired clinical isolates. Additionally, we characterized in vitro strain-associated differences in virulence for macrophages and described a potential inverse relationship between virulence in the IP mouse model of some strains and in the macrophage phagocytosis assay. Strains which were more virulent for mice (e.g., HBPU10304a) were often less virulent in the macrophage assays, as determined by several parameters such as intracellular bacterial replication and host cell cytotoxicity.

Citing Articles

A Novel Virulent Clinical Isolate of Burkholderia pseudomallei Imported from Thailand Exhibiting Resistance to Trimethoprim-Sulfamethoxazole.

Amit S, Gur D, Aftalion M, Biber A, David P, Cohen-Gihon I Am J Trop Med Hyg. 2024; 112(1):116-123.

PMID: 39437772 PMC: 11720787. DOI: 10.4269/ajtmh.24-0231.


Virulence of Burkholderia pseudomallei ATS2021 Unintentionally Imported to United States in Aromatherapy Spray.

Cote C, Mlynek K, Klimko C, Biryukov S, Mou S, Hunter M Emerg Infect Dis. 2024; 30(10):2056-2069.

PMID: 39320153 PMC: 11431913. DOI: 10.3201/eid3010.240084.


Marmosets as models of infectious diseases.

Herron I, Laws T, Nelson M Front Cell Infect Microbiol. 2024; 14:1340017.

PMID: 38465237 PMC: 10921895. DOI: 10.3389/fcimb.2024.1340017.


Complete genome sequences of nine strains.

Nishida T, Hiramatsu Y, Shinzawa N, Horino A, Mori S, Horiguchi Y Microbiol Resour Announc. 2023; 12(9):e0040023.

PMID: 37489889 PMC: 10508117. DOI: 10.1128/MRA.00400-23.


Efficacy of ceftazidime in a murine model following a lethal aerosol exposure to Burkholderia pseudomallei.

Pfefferle D, Hackett M, Anderson M, Gibbs S, Henning L, Joice A Sci Rep. 2023; 13(1):4047.

PMID: 36899021 PMC: 10006082. DOI: 10.1038/s41598-023-31131-8.


References
1.
Utaisincharoen P, Anuntagool N, Arjcharoen S, Limposuwan K, Chaisuriya P, Sirisinha S . Induction of iNOS expression and antimicrobial activity by interferon (IFN)-beta is distinct from IFN-gamma in Burkholderia pseudomallei-infected mouse macrophages. Clin Exp Immunol. 2004; 136(2):277-83. PMC: 1809035. DOI: 10.1111/j.1365-2249.2004.02445.x. View

2.
Scott A, Burtnick M, Stokes M, Whelan A, Williamson E, Atkins T . Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis. Infect Immun. 2014; 82(8):3206-13. PMC: 4136211. DOI: 10.1128/IAI.01847-14. View

3.
Rammaert B, Beaute J, Borand L, Hem S, Buchy P, Goyet S . Pulmonary melioidosis in Cambodia: a prospective study. BMC Infect Dis. 2011; 11:126. PMC: 3117704. DOI: 10.1186/1471-2334-11-126. View

4.
Allwood E, Devenish R, Prescott M, Adler B, Boyce J . Strategies for Intracellular Survival of Burkholderia pseudomallei. Front Microbiol. 2011; 2:170. PMC: 3159172. DOI: 10.3389/fmicb.2011.00170. View

5.
Ngauy V, Lemeshev Y, Sadkowski L, Crawford G . Cutaneous melioidosis in a man who was taken as a prisoner of war by the Japanese during World War II. J Clin Microbiol. 2005; 43(2):970-2. PMC: 548040. DOI: 10.1128/JCM.43.2.970-972.2005. View